Autologous hematological stem cell transplantation (ASCT) is used for the treatment of many hematological and several solid cancers. ASCT, however, has proven disappointing as a therapeutic strategy for breast cancer. Our group and others have previously shown that breast cancer micrometastases found in patients' apheresis products (APs) predict shorter progression-free and overall survival. The implications of this finding are twofold: (i) contaminating tumor cells (CTCs) in AP reflect a higher systemic disease burden and/or (ii) reinfused CTCs contribute to relapse/progressive disease. To date, purging strategies have been disappointing. We have previously demonstrated the oncolytic properties of reovirus in in vitro, in vivo and ex vivo systems. In the present study, we tested the hypothesis that reovirus purges CTCs in a breast cancer cell line purging model. Reovirus-infected human breast cancer cell lines (HTB 133, HTB 132, SKBR3 and MCF7) exhibited cell death within days. Admixtures of AP with cells from breast tumor cell lines, which were then exposed to reovirus, showed complete purging of CTCs (assessed via flow cytometry/tumor cell outgrowth analysis) without deleterious effect on CD34 þ cells. Our results provide preclinical support for the ex vivo use of reovirus as a purging modality for breast cancer during ASCT.
reovirus Breast cancer, defined as the world's most common female malignancy, 1 ranks second only to lung cancer among cancer deaths in women. 2 Due to the considerable progress made in the control and treatment of invasive breast cancer during the past decade, breast cancer-related mortality rates are declining in several countries. 3, 4 Despite this progress, the incidence of breast cancer continues to rise globally 1, 4 and an ever-increasing number of women are dying, underlining the need for better treatment options.
High-dose chemotherapy (HDC) followed by autologous peripheral blood stem cell transplantation (ASCT) was a common treatment for breast cancer in the 1990s. Although this treatment modality has largely fallen out of favor due to the negative early results of randomized controlled trials, several methodological concerns have produced definitive negative conclusions, perhaps prematurely. [5] [6] [7] The clinical benefits observed in recent reports are more encouraging, re-emphasizing the possible role of HDC for breast cancer. 6, 8 The contribution of minimal residual disease (MRD) to the development of relapse is likely to be a major problem associated with ASCT. Autograft contamination of clonogenic malignant cells is a frequent occurrence and genemarking studies have provided evidence that tumor cells within autografts could contribute to relapse. [9] [10] [11] Thus, researchers have postulated a variety of purging strategies to rid autografts of contaminating tumor cells (CTCs). [12] [13] [14] [15] [16] [17] [18] [19] The ideal purging procedure should preferentially destroy contaminating tumor cells while sparing the number and function of hematopoietic stem cells. The present investigation explores the possibility of using reovirus, a benign common environmental double-stranded RNA virus, as a purging strategy during autotransplantion.
Reovirus is a nonenveloped double-stranded RNA virus containing a segmented genome. Reovirus infections in humans are generally restricted to the upper respiratory and gastrointestinal tract and, clinically, this virus is not considered significant. 20 When reovirus-resistant murine NIH 3T3 cells are transformed with oncogenes such as v-erbB 2 , sos and ras, reovirus susceptibility is conferred. 21 It is likely that reovirus exploits an activated Ras/oncogenic signalling pathway, taking advantage of the inhibition of the double-stranded RNA activated protein kinase (PKR) found in these cells. 22 In all, 30% of all cancers express ras mutations and this number exceeds 50% when mutations in elements up/down stream of ras are considered. Recent data have implicated the Ras/RalGEF/p38 pathway in an NIH 3T3 model system. 23 Confirming this assumption, the oncolytic ability of reovirus against myriad neoplasms including breast, prostate, colorectal and hematological cancers has been shown by our group. [24] [25] [26] [27] [28] [29] [30] The results of the present study implicate a possible role for reovirus as a successful purging strategy for contaminating breast cancer.
Materials and methods

Cell lines
Established breast cell lines HTB133, HTB 132, MCF7, SKBR3 and L929 were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). All cells were grown in DMEM media (Gibco BRL, Burlington, Ontario) containing 10% fetal bovine serum (FBS), supplemented with sodium pyruvate.
Reovirus
Reovirus serotype 3 (strain Dearing) was propagated in L929 cells grown in suspension in Joklik's modified Eagle's medium (JMEM, Gibco BRL, Berlington, Ontario) containing 5% FBS. For virus purification, the protocol of Smith et al (1969) was utilized, with the exception that bmercaptoethanol was omitted from the extraction buffer. 31 Live virus was inactivated following exposure to UV light for 45 min. Sterility and inactivation was confirmed by plating onto susceptible cell monolayers and culturing for up to 1 week.
Patient apheresis product (AP)
All AP used in the present study was collected from patients registered at the Tom Baker Cancer Centre, Calgary, Canada, following informed consent in compliance with the local Institutional Review Board. Mononuclear AP cells were washed in phosphate-buffered saline (PBS) and cultured in RPMI 1640 medium supplemented with 10% FBS.
Cytopathic effect/immunohistochemistry (IHC) of reovirus
Cell line monolayers grown to 60% confluency were infected with reovirus at a multiplicity of infection (MOI) of 40 plaque forming units (PFUs)/cell (previously shown to produce maximal oncolysis). To assess the cytopathic effect, cells were photographed under a light microscope at 2, 24, 48 and 72 h post-infection. For IHC analysis, reovirus-treated and untreated cell monolayers were trypsinized at 2, 24 and 72 h post-infection, and 3 Â 10 5 cells were used for the staining procedure. Intracellular staining was performed following permeabilization of cell membranes (IntraPrep, Beckman-Coulter, Hialeah, FL, USA), followed by primary antibody (rabbit polyclonal anti-reovirus type 3 serum, a gift from Dr P Lee) diluted 1/20 in PBS and secondary antibody (goat anti-rabbit IgG -FITC, DAKO, Mississauga, Ontario) diluted 1/100 in PBS staining. Immunofluorescent cells were photographed under a UV microscope (NikonY -THS, Japan). Cytokeratin (CTK) positivity of HTB133 cells was confirmed by immunofluorescence staining using a monoclonal pan-CTK-FITC antibody (BD Bioscience, San Jose, CA, USA).
Metabolic radiolabeling and immunoprecipitation of reovirus-infected cells
Cancer cell lines and L929 cells grown to 60% confluency were infected with reovirus at a MOI of 40 PFU/cell. To evaluate whether reovirus infects AP cells, cells were cultured in RPMI medium containing 10% FBS and infected with reovirus at 40 MOI.
The medium was replaced with media containing 0.1 mCi/ ml of [ Following further incubation for 12 h at 371C, the cells were washed in PBS and lysed in lysis buffer containing 1% Trition X-100, 0.5% sodium deoxycholate and 1 mM EDTA. Lysates were cleared of debris by centrifugation, and the supernatants were stored at À801C until further use. Immunoprecipitation of the [
35 S]methionine-labelled reovirus proteins was performed using polyclonoal rabbit anti-reovirus serotype 3 serum. 32 Radiolabelled lysates and immunoprecipitated reovirus proteins were subjected to 10% SDS-PAGE, followed by autoradiography.
Viral progeny production in infected breast cell lines
Breast cancer cells were grown in six-well plates and infected with 40 MOI of reovirus. To evaluate virus progeny production, the cells were frozen at À801C at 0 and 72 h post-infection. The frozen plates were subjected to three freeze/thaw cycles and supernatants underwent plaque titration analysis on L929 cells. Three separate experiments were replicated for each cell line
Cell counting and DNA fragmentation
Breast cancer cell lines grown to 60% confluence were either infected with live reovirus (40 MOI), UV-inactivated virus or left untreated for up to 7 days. Cells were harvested at 0, 1, 2, 3, 4 and 7 days post-treatment and 1 ml of cell culture suspension (approximately 1 Â 10 6 cells) was centrifuged for a minute at 450 g. The cell pellet was resuspended in 1 ml of 50 mg/ml of propidium iodide/ RNAse/Trition X-100 (Sigma Chemical Co., St Louis, MO, USA). Flow Countt beads (100 ml; Beckman-Coulter, Brea, CA, USA) were added to this as an internal calibrator and intact cancer cells were assessed using flow cytometry (EPICS XL or FC500, Beckman Coulter).
Enumeration of CD34
þ CD45 þ cells
In order to enumerate CD34 þ stem cells, 10 ml of AP was incubated for 10 min with CD45-FITC (J33 clone, Beckman Coulter) and CD34-PE (581 clone, Beckman Coulter). After addition of 1.0 ml of PBS and 100 ml of Flow Count Fluorospherest (Beckman Coulter), 100 000 cells were analyzed by flow cytometry (EPICS XL or FC500, Beckman Coulter). Cells that were identified as dim CD45 þ , bright CD34 þ , and those forming a discrete cell cluster with larger forward scatter (FS) signals than lymphocytes were enumerated as CD34 þ cells. 33, 34 The absolute CD34 þ cell count was determined directly from the flow cytometer (single-platform analysis) using the Flow Count beads as an internal calibration.
Ex vivo purging model
In order to experimentally attain a tumour burden of 1, 0.1 and 0.01%, HTB 133 human breast cancer cells (CTK positive) were admixed with AP cultured in RPMI 1640 medium containing 10% FBS. The admixed cells were either infected with reovirus (40 MOI) or left untreated and incubated for 3 days.
Samples of admixed cell populations were evaluated for residual CTK-positive cells using flow cytometry on 0 and 3 days post-purging. To further evaluate whether the cell admixing procedure and/or viral infection affects CD34 þ cells, a sample of the admixed cell population was analyzed for CD34 þ 45 þ cells counts 3 days postviral treatment (as described above). Both purged and unpurged products were re-cultured in DMEM medium to confirm the purging efficacy and at 6 days viable breast cell numbers were enumerated using flow cytometry for CTK-positive cells.
Statistical analysis
The final PFU values were transformed using the natural logarithm to meet the key assumptions of the paired t-test, that is, variance between the two time points (0 and 72 h) is the same within each cell line. A Student's t-test was performed with the log-transformed values.
Results
In vitro oncolysis in human malignant breast cell lines
We investigated the susceptibility of established breast cancer cell lines to reovirus infection at an MOI of 40. logarithmic growth phase when continuously passaged. To ensure that cell lysis was due to viral replication, HTB 133 cells were incubated with rabbit anti-reovirus antibody, followed by FITC-conjugated goat-anti-rabbit IgG. As shown in Figure 1b , intracellular viral antigens could be detected as early as 2 h post-infection, and at 72 h complete lysis was evident. Similarly, breast cancer cell lines when cultured with either reovirus, UV-inactivated virus or no virus at days 0, 1, 2, 3, 4 and 7 days post-virus infection and analyzed for viable cell counts using propidium iodide demonstrated a decrease in cell number as early as 2 days post-virus infection. In contrast to virus-treated cells, an exponential increase in the uninfected or dead virus-treated cells was observed (Figure 2 ). The one-sample paired Student t-test revealed significant differences in viral progeny production between 0 and 72 h post-infection for all breast cell lines (Po0.05). The maximum amount of viral progeny was produced in HTB 132 cells at 72 h and this is in agreement with the kinetics of killing of these tumour cells. As revealed by the metabolic labelling and flow cytometry data, this cell line had delayed kinetics of killing compared to the other cell lines and more virus production may be necessary for oncolysis.
In contrast to the breast cancer cell lines, the metabolic labelling of AP cells did not show virus protein synthesis even after 72 h of infection. Figure 5a shows the metabolic labelling of AP cells, as well as L929 and HTB 133 cells run in parallel as controls. Figure 5b shows the immunoprecipitated lysates of the same reactions. Both L929 and HTB 133 cells were labelled and harvested after 24 h of virus infection. The appearance of lambda (l), mu (m) and sigma (s) viral protein bands were evident in both L929 and HTB (Figure 5b ) are likely to be due to the polyclonal antibody cross-reactivity with host protein, since they do not correspond to any known reovirus protein and appear at 12 h even in the reovirus-untreated samples (data not shown). Following labelling, the cells were lysed and the cellular proteins were subjected to SDS-PAGE. Reovirus proteins (l, m and s) are indicated on the left. In the HTB 133 and SKBR3 panels, immunoprecipitated lysates (24 h untreated or virus-treated) were run as viral markers in the first two lanes. Viral protein synthesis occurred at the expense of host protein synthesis in the cell lines exposed to reovirus.
Reovirus efficiently purges breast tumor cells in AP
The metabolic labelling data indicate that reovirus does not infect CD34 þ cells and in a previous report we have shown that exposure of selected CD34-positive cells to reovirus does not affect CD34 þ 45 þ cell counts or their colonyforming potentials even at 5 days post-virus infection. 29 We next sought to determine if breast cancer cells seeded into apheresis cell cultures would be sensitive to reovirus at an MOI of 40. HTB 133 cells were mixed with AP cells to simulate tumour burdens of 1, 0.1 and 0.01% and purged with reovirus for 3 days. As shown in Figure 6a , no CTKpositive cells were detected at 3 days post-purging, indicating 100% purging efficacy of reovirus. When reovirus-treated admixed samples were transferred to HDMEM medium (conducive for HTB 133 cell growth), significant breast cell growth was detected in the virusuntreated cells following 6 days of culture (Figure 6b ). In comparison, no HTB 133 cell growth was detected in the purged samples, confirming successful purging. In order to assess whether purging with reovirus would affect CD34 þ cells, purged and unpurged samples were assessed for CD34 þ cell counts with flow cytometry. As shown in Figure 7 , reovirus treatment in either of these experiments did not affect the CD34 þ cells, confirming reovirus resistance of CD34 þ cells.
Discussion
The use of hematopoietic stem cell rescue followed by myeloablative or high-dose chemotherapy increases the response rates and may yet hold promise for advanced and/or metastatic breast cancer patients. Recent Cochrane reviews of ASCT in this patient population suggest a significant event-free survival benefit; however, no overall survival (OS) benefit to date. 35, 36 Two possible explanations for the lack of improved survival are felt to be residual disease in vivo post high-dose chemotherapy and/or the possibility of contamination of the autograft by tumour cells. With regard to the latter, CTCs within the harvested stem cell product have been detected in patients with stage II, III and IV breast cancer. 8, [37] [38] [39] [40] [41] [42] The presence of CTCs within autografts is likely to be partially responsible for the recurrence of disease after autotransplantation and are associated with a worse outcome. 11, 39, 43, 44 A recent study conducted in our cancer centre has revealed that greater than 3 CTC per 1 Â 10 6 AP cells negatively affects OS and disease-free survival. 8 Similarly, Neito et al have recently shown that CTC in high-risk breast cancer AP collections is associated with inferior event-free and OS. 42 Reovirus is a tumour-selective dsRNA virus with a wide spectrum of oncolytic capability in vitro, ex vivo and in vivo, against glioma, prostate, colorectal, ovarian, breast and hematopoeitic malignancies. [24] [25] [26] [27] [28] [29] [30] Recently, we reported the successful purging of chronic lymphocytic lymphoma, diffuse large B-cell lymphoma, Waldenstrom's disease and multiple myeloma cell lines and ex vivo patient specimens using reovirus. 29 We now demonstrate in a preclinical setting that a similar strategy of purging may extend to high-risk breast cancer patients that undergo ASCT.
The human mammary carcinoma cell lines, HTB 133, HTB 132, SKBR3 and MCF7, demonstrate significant susceptibility to reovirus. The majority of cell death was obtained by 72 h post viral infection. Reovirus protein synthesis, immunofluorescence staining of reovirus proteins and flow-cytometric analysis of viable cells and viral progeny production further confirm reovirus susceptibility in these cells. Of interest, mutated forms of the ras gene are rare (o5%) in breast cancer and the cell lines used in this study do not have mutations in the ras gene itself. 45 However, it is believed that activations of the Ras signalling pathway (via upstream or downstream elements) are important in the initiation and progression of breast cancer. [46] [47] [48] [49] [50] [51] [52] [53] Consistent with this, Eckert et al 45 using an indirect Ras activation assay have demonstrated activated Ras in three of the four cell lines, that is, MCF7, SKBR3 and HTB 132 (MDA-MB 468). HTB 133 (T-47D) may have alternate, not yet described signalling pathways that reovirus may usurp. Further, a recent report from our laboratories has implicated the activation of the Ras/Ral GEF/p38 pathway in an NIH 3T3 model as being permissive for reovirus oncolysis. 23 These pathways appear to abrogate the antiviral response by inhibiting the doublestranded RNA-activated protein kinase (PKR), and thus allow reovirus infection.
For this to be shown as an effective and safe purging agent, it was important to test for the possible negative effects of reovirus on AP cells harvested for marrow repopulation. Metabolic ([ present study we do not see any differences in CD34 þ / 45 þ cell number in purged or unpurged AP. This ex vivo purging model system indicates that it is possible to achieve complete purging up to 1% of tumour burden. Frequently, the clinical tumour burden encountered in AP cells is in the order of o0.01%, 54 and falls well within the range of successful purging seen in our experiments.
Reovirus administration to immunocompromised SCID/ NOD mice is associated with vascular inflammation and death usually occurs within 35-40 days depending on the dose and route of administration. 55 Interestingly, nude mice receiving 5 Â 10 8 PFUs of reovirus when administered intravenously or intracraneally did not show any adverse effects in our and other's laboratories. 30, 56 Further, primates receiving daily intravenous injections of 5 Â 10 8 PFUs of reovirus exhibited no toxicities (M Coffey, personal communication). There is, however, still a theoretical concern that, if this purging strategy were translated into a patient population, viable reovirus would be administered to the patient at the time of stem cell re-infusion, with the possibility of significant toxicity in a myelosuppressed host, reminiscent of the immunocompromised SCID/NOD mice. To address this concern, we have previously demonstrated that DMSO/cryopreserved AP treatment significantly reduces reovirus titers. 29 An ongoing phase 1 trial of intravenous administration of reovirus in cancer patients and a second trial of systemic reovirus in haematological malignancies, including post-allogeneic transplant patients is planned. Further, in a human phase 1 clinical trial viremia was detected in 2/8 patients receiving intralesional reovirus treatment (Morris et al, in preparation) and the 18 patients entered into the study had no grade 3/4 toxicity as defined by the NCI-CTG and toxicity criteria. 57 The majority of patients in this study had neutralizing antibodies at baseline, suggesting previous seroconversion.
Investigation into the role of passive immunization of antireovirus antibodies as a viable rescue procedure for reovirus toxicity in NOD/SCID mice is ongoing. Prior to a phase I purging trial, reovirus toxicities in purged APs need to be tested in an immunosuppressed primate model system, as there still remains a theoretical risk of reinfusion of viable reovirus to patients with the AP. An additional strategy would be to pre-immunize patients against reovirus antigens pre-transplantation to present natural immunity at the time of transplant.
The use of virus-mediated oncolysis as a purging strategy has been exploited in the past. Recently, adenovirus-based purging techniques have been described for breast cancer and neuroblastoma. [58] [59] [60] These, however, have the limitation of transfection efficiency and possible hepatic toxicities. Our findings suggest that reovirus can be used as an efficient ex vivo purging agent in autologous transplantation for breast cancer, that requires minimal AP cell manipulation and selectively targets breast cancer cells while sparing CD34 þ cells.
